Pressmeddelanden, rapporter och bolagsmeddelande för PILA PHARMA AB

PILA PHARMA AB har kallat till årsstämma den 18 april 2024 hos MAQS Advokatbyrå i Malmö. Aktieägare som önskar delta ska vara registrerade i aktieboken senast den 10 april 2024 och anmäla deltagande senast den 15 april. Dagordningen inkluderar bland annat godkännande av årsredovisning, val av styrelse och revisor, samt beslut om eventuell nyemission av aktier. Styrelsen föreslår att ingen utdelning görs för räkenskapsåret 2023. Valberedningen föreslår omval av flera nuvarande styrelseledamöter och nyval av Lasse Richter Petersen. Revisionsbolaget Deloitte föreslås för omval som revisor.

Founder and CEO of PILA PHARMA AB, Dorte X. Gram, has been nominated to become the company's next Chairman of the Board. The announcement was made in the call for the company's Annual General Meeting, scheduled for 18 April 2024. If Gram receives shareholder support and becomes Chairman, she will step down as CEO and the company will search for a replacement. PILA PHARMA is a Swedish biotech firm focused on developing TRPV1 antagonists for the treatment of type 2 diabetes and other inflammatory diseases. The company's share ticker, PILA, is traded on Nasdaq First North Growth Market, Sweden.

Swedish biotech company, PILA PHARMA AB, has announced a series of upcoming investor events in Denmark and Sweden, both in-person and online, from 21 March to 18 April 2024. The events will feature discussions by the company's CEO and Founder, Dorte X. Gram, on the company's potential novel pill treatment for diabetes, obesity, and related conditions. PILA PHARMA is focused on the development of TRPV1 antagonists for the treatment of type 2 diabetes and other inflammatory diseases. The company's main development candidate is XEN-D0501, a selective, synthetic potent small molecule TRPV1 antagonist. PILA PHARMA's shares are traded on the Nasdaq First North Growth Market in Sweden.